NCT06334484

Brief Summary

Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by pancreatic beta cells destruction, resulting in insulin secretion deficit (1). Insulin therapy is essential in the therapeutical management of subjects with T1DM (1). The Diabetes Complications and Control Trial (DCCT) has showed that intensive insulin treatment was associated with a reduction in the onset of complications related to diabetes. In recent years, treatment of T1DM evolved rapidly because of the significant improvements in the use of technology (2). With the spread of continuous glucose monitoring (CGM) systems, standardized metrics, summarizing time spent within optimal glucose range (time in range - TIR), time below target glucose range (TBR) and time above target glucose range (TAR), have become commonly used metrics in clinical practice (3,4). Furthermore, glucose management indicator (GMI) estimates glycated haemoglobin from the average glucose level of CGM readings for 14 days and coefficient of variation (CV) evaluates the amplitude of glucose excursions. Advanced hybrid closed loop (AHCL) systems combine insulin pump infusion and real time CGM (rtCGM) data through an algorithm: they suspend insulin infusion if hypoglycaemia is expected and can administer automatic corrective boluses in case of hyperglycaemia (6). Different algorithms, as Model Predictive Control (MPC) or Proportional-Integral-Derivative (PID), are used by different systems available on the market and are currently used in clinical practice. Overall, AHCL are associated with improvement of glycated hemoglobin (HbA1c) and TIR opening to the possibility to gain even tighter glycemic control. The primary objective is therefore to evaluate the glycemic improvement expressed through adjunctive CGM metrics in subjects with T1DM 24 months after starting AHCL therapy

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 21, 2024

Completed
5 days until next milestone

Study Start

First participant enrolled

March 26, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 28, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 26, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 26, 2026

Completed
Last Updated

March 28, 2024

Status Verified

March 1, 2024

Enrollment Period

1.5 years

First QC Date

March 21, 2024

Last Update Submit

March 21, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • change in time spent in tighter glucose range after 24 months of hybrid closed loop system

    time spent in tighter glucose range (TiTR - 70-140 mg/dl or 3.9-7.8 mmol/l)

    24 months

Interventions

Collect data from advanced hybrid closed loop users

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects with T1DM who started AHCL for at least 6 months.

You may qualify if:

  • Informed consent signed before any activity related to the study
  • Age ≥18 years, both sexes
  • Start of AHCL for at least 6 months before enrollment (from 01/01/2021 to 31/12/2023).

You may not qualify if:

  • \. Diagnosis of type 2 diabetes mellitus or other forms of diabetes, such as metasteroid diabetes, secondary to pancreatectomy, related to pancreatitis or secondary to endocrinological disorders, gestational diabetes, maturity-onset diabetes of the young (MODY).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione Policlinico Universitario A. Gemelli IRCCS

Roma, 00168, Italy

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Dario DFP Pitocco, Prof.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 21, 2024

First Posted

March 28, 2024

Study Start

March 26, 2024

Primary Completion

September 26, 2025

Study Completion

March 26, 2026

Last Updated

March 28, 2024

Record last verified: 2024-03

Locations